Transcatheter endocardial alginate-hydrogel implantation for the treatment of a patient with non-responsive heart failure on cardiac resynchronization therapy defibrillator:a case report
10.3969/j.issn.1004-8812.2024.08.009
- VernacularTitle:经导管心内膜注射植入性海藻酸盐水凝胶治疗心脏再同步化治疗除颤器无应答心力衰竭患者1例
- Author:
Cun-Jun ZHU
1
;
Bo WANG
;
Chao GAO
;
Min SHEN
;
Tao SU
;
Ru-Tao WANG
;
Fang-Jun MOU
;
Xiao-Na CHEN
;
Fei LI
;
Ling TAO
Author Information
1. 中国人民解放军空军军医大学第一附属医院心血管内科,陕西西安 710032
- Keywords:
Heart failure;
Alginate-hydrogel;
Transcatheter endocardial intervention
- From:
Chinese Journal of Interventional Cardiology
2024;32(8):468-471
- CountryChina
- Language:Chinese
-
Abstract:
Heart failure(HF)is the end stage of almost all cardiovascular diseases,including coronary heart disease and structural heart disease.For end-stage HF,medications and cardiac assist devices have limited therapeutic effects,and heart transplantation is associated with donor shortage and immune rejection.Alginate hydrogel has the ability to mechanically support and induce cardiac tissue regeneration and repair.In March 2021,we conducted the world's first transcatheter endocardial alginate-hydrogel implantation in patients with end-stage heart failure,and explored the safety and feasibility of the treatment.Given that patients with heart failure who had undergone cardiac resynchronization therapy defibrillator(CRT-D)were excluded from previous studies,this paper is the first to report a case of transcatheter endocardial alginate-hydrogel implantation in a patient with heart failure who did not respond to CRT-D,with a significant reduction in the number of visits to the doctor and a significant improvement in the quality of life during the post-procedure follow-up,which may expand the indications for the use of this technology.
